My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

18.81 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Don't Buy Summit Therapeutics Until This Big Thing Happen ↗

December 03, 2025

This biotech company is rolling the dice with a planned regulatory submission.

Via The Motley Fool

2 Monster Stocks in the Making to Buy and Hold ↗

December 02, 2025

There's still time to get in on these rising stars.

Via The Motley Fool

Summit SMMT Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Summit SMMT Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China

November 07, 2025

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Stock Sparks Retail Buzz After Ivonescimab Combo Cuts Cancer Progression Risk By 40% ↗

October 19, 2025

Via Stocktwits

An Overview of Summit Therapeutics's Earnings ↗

October 17, 2025

Via Benzinga

Summit Therapeutics to Present at Upcoming Investor Conferences

November 04, 2025

From Summit Therapeutics

Via Business Wire

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

October 31, 2025

From Summit Therapeutics

Via Business Wire

Alpha Buying: When Insiders Buy Big & Why It Works in Every Market ↗

October 30, 2025

Via Benzinga

Why Wall Street Is Backing These 3 Comeback Stocks ↗

October 28, 2025

Via MarketBeat

1 Monster Stock in the Making to Buy and Hold ↗

October 27, 2025

The company's prospects improve with every clinical win.

Via The Motley Fool

Summit Therapeutics: A Risky Bet in the Biotech Arena? ↗

October 24, 2025

Join us as we dissect Summit Therapeutics' potential in the biotech sector. Can their promising drug Ansuvimab overcome the odds, or is this stock a risky bet?

Via The Motley Fool

Summit Therapeutics Raises $500 Million in Private Placement

October 22, 2025

From Summit Therapeutics

Via Business Wire

What's Going On With Summit Therapeutics Stock On Monday? ↗

October 20, 2025

Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late 2025.

Via Benzinga

Retail Investors' Top Stocks With Earnings This Week: Tesla, Netflix, Intel and More ↗

October 20, 2025

Retail investors prepare for the first busy week in the Q3 earnings season, with Tesla, Netflix and Intel on deck.

Via Benzinga

Summit Therapeutics Inc (NASDAQ:SMMT) Reports Wider-Than-Expected Q3 2025 Loss ↗

October 20, 2025

Summit Therapeutics reported a wider-than-expected Q3 2025 loss but is advancing its lead drug, ivonescimab, toward a key FDA submission.

Via Chartmill

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

October 20, 2025

From Summit Therapeutics

Via Business Wire

Earnings Scheduled For October 20, 2025 ↗

October 20, 2025

Via Benzinga

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

October 19, 2025

From Summit Therapeutics

Via Business Wire

Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer

October 17, 2025

From Summit Therapeutics

Via Business Wire

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

October 15, 2025

From Summit Therapeutics

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

October 08, 2025

Via Benzinga

1 Monster Stock in the Making to Buy and Hold ↗

October 05, 2025

This biotech company was relatively unknown a few years ago.

Via The Motley Fool

Alpha Buying: The 3 Stocks That Just Got This $1 Million Vote of Confidence ↗

October 01, 2025

Via Benzinga

Intel, Marvell, Electronic Arts Are Among The Top 10 Large-Cap Gainers Last Week (Sep. 22 - Sep. 26): Are The Others In Your Portfolio? ↗

September 28, 2025

These ten large-cap stocks were top performers last week. Are they a part of your portfolio?

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

September 24, 2025

From Pomerantz LLP

Via GlobeNewswire

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 24, 2025

From Summit Therapeutics

Via Business Wire

HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025

September 24, 2025

From Summit Therapeutics

Via Business Wire

Nvidia High-Fives Palantir, Rocket Lab — On This List Of '10-Bagger' Legends ↗

September 23, 2025

Ten stocks in the large-cap Russell 1000 index have achieved at least 1,000% returns since the October 2022 bull market bottom, showcasing the power and volatility of high-growth companies in a rapidly...

Via Benzinga

This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

September 17, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.